종근당의 배곧 3925억 투자, 위고비·CKD-510 별개 제조축 시험

Chong Kun Dang's 392.5 billion won investment in the Baegot Bio Complex creates a strategically separate manufacturing axis from its current revenue drivers (imported products) and future value anchor (CKD-510). The company targets global CMO/CDMO contracts for biosimilar production, but success hinges on demonstrating GMP-certified production capacity and securing external orders after 2028 completion. This capital deployment during margin compression underscores both growth ambitions and execution risks, with external contract materialization as the critical valuation inflection point.